Scientific Program Oncology

Day I (4th of April 2024)

AULA MAGNA (Ground floor, B Building)
13:00
Official opening
Dan Gheonea, Marcel Tanțău, Răzvan Curcă, Florin Burada
13:30
Connections Gastroenterology - Oncology - Genetics
Dan Gheonea, Michael Schenker, Florin Burada
14:30
Not only cancer kills…also Obesity
Cătălina Poiană, Bogdan Timar
15:00
Coffee break
15:30
Pipeline drugs in oncology
Răzvan Prisada - President ANMDM Romania
Michael Schenker - President Oncology Committee of Ministry of Health
16:30
The importance on the G6 universities in medical education of population

•G6-UMF Symposia dedicated to World Health Day
Rectors of the Romanian Medical Universities: Leonard Azamfirei (UMFST George Emil Palade Tg. Mureș), Anca Buzoianu (UMF Iuliu Hațieganu Cluj), Octavian Crețu (UMF Victor Babeș Timișoara), Dan Gheonea (UMF Craiova), Viorel Jinga (UMF Carol Davila București), Viorel Scripcariu (UMF Gr.T. Popa Iași)
17:30
The hub of innovation - a strong partnership G6-UMF-MS-LAWG
Teodor Blidaru (Manager Innovation Hub), Viorel Jinga (President G6-UMF), Stefan Strilciuc (MS representative), Frank Loeffler (President LAWG), Radu Rășinar (Vice-President LAWG), Adriana Stara (Board Member LAWG)
18:00
The genetic origins of Romanians through the fog of the times
Mihai Netea – Spinoza Prize Laureate, Radboud University, The Netherlands


Day II (5th of April 2024)

GASTROENTEROLOGY HALL (3rd floor, A’ Building)
08:00
Neuroendocrine tumors
Chairmen: Cătălina Poiană, Adina Croitoru, Mircea Diculescu

• [08:00 - 08:15] New classifications of NET
Cătălina Poiană

• [08:15 - 08:30] Diagnosis of gastro-entero-pancreatic NET
Mircea Diculescu

• [08:30 - 08:45] News in systemic treatment
Adina Croitoru

• [08:45 - 09:00] Insulinoma successfully treated by EUS-guided RFA
Bogdan Ungureanu, Dan Gheonea
09:00
Patient Blood Management (PBM) – The role of multidisciplinary team
Chairmen: Dan Gheonea, Michael Schenker, Lucian Negreanu

Discussions panel:
• Silvius Negoiță (Intensive Care)
• Răzvan Ene (Orthopedy)
• Lucian Negreanu (Gastroenterology)
• Stelian Mogoantă (General surgery)
• Dominic Iliescu (Gynecology)
Supported by CSL Vifor
10:30
Coffee break
ONCOLOGY HALL (2nd floor, A’ Building)
11:00
BREAST CANCER – Session 1
Chairmen: Laura Mazilu, Serban Negru, Laurentia Gales, Michael Schenker

• [11:00 - 11:30] Verzenios - proven efficacy demonstrated in both EBC and MBC
Discussions panel:
- Laura Mazilu
- Serban Negru
Supported by Eli Lilly

• [11:30 - 11:50] Real-world experience with Palbociclib in Romania in patients with a/mBCHR+/HER2-
Larisa Badau
Supported by Pfizer

• [11:50 - 12:10] Optimizing treatment approach for HR+ HER2- mBC patients with visceral mets and/or aggressive disease
Cornelia Nițipir
Supported by Novartis

• [12:10 - 12:40] Pannel discussion – IO in different settings of TNBC
           • KEYTRUDA in early TNBC - Keynote 522 study
           • KEYTRUDA in advanced TNBC - Keynote 355 study
Discussions panel:
- Nelly Cherciu
- Laurentia Gales
Supported by MSD

• [12:40- 13:00] The role of sacituzumab govitecan in mTNBC
Cornelia Nițipir
Supported by Gilead

•[13:00- 13:20] Caelyx in current practice
Dana Stănculeanu
Supported by Baxter

•[13:20- 13:30] Discussions & Conclusions
13:30
Lunch break
14:30
BREAST CANCER – Session 2
Chairmen: Cornelia Nițipir, Dana Stănculeanu, Amedeia Nita, Michael Schenker

• [14:30 - 14:50] Transforming the residual disease in eBC HER2+
Dana Stănculeanu
Supported by Roche

• [14:50 - 15:10] DESTINY - Breast03: A new era in the treatment of patients with HER2+ mBC
Amedeia Nita
Supported by AstraZeneca

• [15:10 - 15:30] Evolution of the HER2 spectrum: targeting of HER2 Low in the treatment of patients with mBC
Cornelia Nițipir
Supported by AstraZeneca

• [15:30 - 15:40] Discussions & Conclusions
15:40
DIGESTIVE MALIGNANT TUMORS – Session 1
Chairmen: Adina Croitoru, Nelly Cherciu, Dorel Popovici, Michael Schenker

• [15:40 - 16:00] Therapeutic approach of biliary tract cancer in the era of immunotherapy
Nelly Cherciu
Supported by AstraZeneca

• [16:00- 16:15] Treatment options in advanced HCC
Adina Croitoru
Supported by Roche

• [16:15 - 16:30] HCC management. What else can we expect from TKIs?
Dorel Popovici
Supported by Ipsen

• [16:30 - 17:00] RIPRETINIB for Advanced GIST & Cancer risk in Acute Hepatic Porphyria - GIVOSIRAN
RIPRETINIB - A novel switch-control TKI in advanced GIST
GIVOSIRAN - Cancer risk in Acute Hepatic Porphyria
Discussions panel:
- Adina Croitoru
- Lucian Negreanu
Supported by Genesis
17:00
Coffee break
17:20
DIGESTIVE MALIGNANT TUMORS – Session 2
Chairmen: Cornelia Nițipir, Amedeia Nita, Ioana Luca, Michael Schenker

• [17:20 - 17:35] ERBITUX: the anti-EGFR that prolongs survival of patients with mCRC RASwt
Ioana Luca
Supported by Merck

• [17:35 - 17:50] The management of patients with metastatic colorectal carcinoma in the third-line of treatment
Adina Croitoru
Supported by Servier

• [17:50 - 18:05] New perspective on the treatment of patients with MSI-H mCRC
Nelly Cherciu
Supported by Bristol Myers Squibb

• [18:05 - 18:20] A new standard is emerging: OPDIVO + chemotherapy as first-line treatment for advanced gastric cancer/ GEJ/ esophageal adenocarcinoma (CheckMate 649)
Amedeia Nita
Supported by Bristol Myers Squibb

• [18:20 - 18:50] Metastatic colorectal carcinoma with MSI-H, challenges in clinical practice
Cornelia Nițipir
Supported by MSD

• [18:50 - 19:00] Discussions & Conclusions


Day III (6th of April 2024)

ONCOLOGY HALL (2nd floor, A’ Building)
08:45
THORACIC MALIGNANT TUMORS – Session 1
Chairmen: Mircea Dediu, Andrei Ungureanu, Razvan Curca, Michael Schenker

• [08:45 - 09:00] The Power to extend Life - Tecentriq in eNSCLC
Razvan Curca
Supported by Roche

• [09:00 - 09:20] Standards of therapy in early stage NSCLC
Laurentia Gales
Supported by AstraZeneca

• [09:20 - 09:50] Keytruda - Long-Term Excellence in mNSCLC:
              • 5 years up-date Keynote 189 & Keynote 407 - focus on patients with brain metastases
              • Side effects to anti PD-1 immunotherapy
Discussions panel:
- Mircea Dediu
- Andrei Ungureanu
Supported by MSD

• [09:50- 10:05] 4-year Clinical Update / Checkmate 9LA: OPDIVO® + YERVOY® with 2 cycles of chemo in mNSCLC
Laura Mazilu
Supported by Bristol Myers Squibb

•[10:05- 10:20] Expanding Possibilities for Patients With I-O Treatment in Malignant Pleural Mesothelioma
Serban Negru
Supported by Bristol Myers Squibb

•[10:20- 10:30] Discussions & Conclusions
10:30
Coffee break
10:45
THORACIC MALIGNANT TUMORS – Session 2
Chairmen: Mircea Dediu, Andrei Ungureanu, Razvan Curca, Michael Schenker

• [10:45 - 11:15] Targeting EGFR along all NSCLC stages
Mircea Dediu

• [11:15- 11:30] Treatment optimisation in NSCLCm ALK+ : the role and importance of Lorlatinib
Razvan Curca
Supported by Pfizer

• [11:30 - 11:45] Therapeutic sequencing in NSCLC ALK+
Mircea Dediu
Supported by Takeda

• [11:45 - 12:05] Standards of therapy in metastatic SCLC
Andrei Ungureanu
Supported by AstraZeneca

• [12:05 - 12:15] Discussions & Conclusions
12:15
Coffee break
12:30
UPDATES ON SPECIFIC SUBJECTS OF INTEREST
Chairmen: Laurentia Gales, Raluca Patru, Serban Negru, Michael Schenker

• [12:30 - 12:50] Transforming Uveal Melanoma: Tebentafusp - A personalized approach to treatment
Laurentia Gales
Supported by Medison-Immunocore

• [12:50- 13:20] Debate on BRAF inhibitors protocol - adjuvance setup/ metastatic setup
Discussions panel:
- Raluca Patru
- Amedeia Nita
Supported by Novartis

• [13:20 - 13:40] The role of supporting therapies with GCSF in management of chemotherapy
Serban Negru
Supported by Accord Healthcare

• [13:40 - 13:55] Comprehensive genomic evaluation - role and indication in digestive malignant tumors
Ana Maria Ciurea

• [13:55 - 14:10] Tumor-Agnostic Testing for NTRK Fusions
Raluca Patru
Supported by Roche
14:10
Lunch break
15:00
URO-GENITAL MALIGNANT TUMORS
Chairmen: Laura Mazilu, Daniela Zob, Razvan Curca, Michael Schenker

• [15:00 - 15:20] Androgen deprivation therapy in prostate cancer -when and how long? Antagonist vs agonist GnRH
Razvan Curca
Supported by Accord Healthcare

• [15:20 - 15:40] Quality of life in patients with prostate cancer
Laura Mazilu
Supported by Astellas pharma

• [15:40 - 16:00] TLynparza + abiraterone, the only reimbursed combination of a PARPi in 1L in mCRPC, independent of mutational status
Raluca Patru
Supported by AstraZeneca

• [16:00 - 16:20] TKI monotherapy in the treatment of renal cell carcinoma
Daniela Zob
Supported by Ipsen

• [16:20 - 16:40] BAVENCIO: choosing the right treatment for the patient with aRCC
Nelly Cherciu

• [16:40 - 17:00] BAVENCIO: prolonging overall survival in patients with advanced urothelial carcinoma
Amedeia Nita
Supported by Merck

• [17:00 - 17:30] Discussions & Conclusions


Day IV (7th of April 2024)

AULA MAGNA (Ground floor, B Building)
10:00
Importance of communication between academics, medicine, and media - Open Session
    • Sources of Well-Being
    • The Rise of the Competitive Physician in the Digital Health Era
• Dorin Dancu (Consultant &Trainer) - INSPIRES
• Andrada Cojocaru (Health Journalist) - TVR Craiova
• Dan Gheonea, Michael Schenker, Florin Burada - UMF Craiova


Orele programului sunt exprimate in ora României